



[HOME](#) > [NEWS](#) > 2017

News



RTI Surgical® Launches Fortilink®-C IBF System, the First 3D Printed Polymer-based Interbody Device

October 25, 2017

Roxane Wergin

Director, Corporate Communications

rwergin@rtix.com

386.418.8888

Designed to Participate In Fusion without Compromising Mechanical Integrity or Radiographic Visibility

ALACHUA, Fla. (October 25, 2017) – [RTI Surgical, Inc.](#) (RTI) (Nasdaq: RTIX), a global surgical implant company, today announced the commercial launch of Fortilink-C IBF System with TETRAfuse® 3D Technology. The Fortilink-C system is the first in a family of devices to incorporate RTI Surgical's TETRAfuse 3D Technology.

"TETRAfuse 3D Technology combines the best characteristics of titanium, allograft bone and PEEK – all in one package," said Grigory Goldberg, M.D., an orthopaedic surgeon practicing in Princeton, N.J. "The Fortilink-C system represents a revolutionary new step in the future of spine surgery."

The Fortilink-C IBF System is the first 3D printed polymer-based, cervical interbody device to incorporate macro, micro and nano-rough features on the entire implant surface— not just on the endplate surfaces. The Fortilink-C device is designed to allow bony ingrowth on all implant surfaces while maintaining radiolucent and bone-like mechanical properties that surgeons expect.

"The Fortilink-C system has ushered in a new beginning for cervical fusion cages – we have gone from iliac crest to cadaver bone to PEEK and titanium, and now, Fortilink-C IBF System with TETRAfuse 3D Technology," said Richard E. Nussbaum, M.D. an orthopaedic surgeon practicing in Sherman Oaks, CA and the first surgeon to implant a Fortilink-C device. "The enhanced implant design increases the surface area and, in an animal model, shows greater circumferential bony ingrowth¹."

"Fortilink-C IBF System demonstrates RTI Surgical's commitment to advancing technologies and delivering innovative clinical solutions that meet the demands of our customers while improving the lives of patients," said Camille Farhat, RTI chief executive officer. "This new innovative platform will have many derivative products, and this, in addition to the [map3® Cellular Allogeneic Bone Graft](#) and our comprehensive spine hardware portfolio, brings us a step closer to a complete offering."

® indicates U.S. trademark registration. All trademarks and/or images are the property of their respective owners or holders.

¹ Data on file RTI Surgical, Inc. Performance data from animal models may not be representative of performance in humans.

About RTI Surgical Inc.

[RTI Surgical](#) is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI's implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and

uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtx.com or the SEC's website at www.sec.gov.

###

Media Contacts

Roxane Wergin

Director, Corporate Communications

rwergin@rtix.com

386.418.8888 Ext. 4414

Erin Morton, APR, CPRC

Senior Manager, Corporate Communications & Family Services - RTI Donor Services

emorton@rtix.com

386.418.8888 Ext. 4218

Copyright 2017 RTI Surgical®, Inc All rights reserved • [Terms Of Use](#) • [EU / Swiss Safe Harbor Privacy Policy](#)